CN104013595A - 一种盐酸司来吉兰制剂及其制备工艺 - Google Patents
一种盐酸司来吉兰制剂及其制备工艺 Download PDFInfo
- Publication number
- CN104013595A CN104013595A CN201310065036.3A CN201310065036A CN104013595A CN 104013595 A CN104013595 A CN 104013595A CN 201310065036 A CN201310065036 A CN 201310065036A CN 104013595 A CN104013595 A CN 104013595A
- Authority
- CN
- China
- Prior art keywords
- preparation
- selegilinehydrochloride
- capsule
- parts
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title abstract 8
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 title abstract 4
- 229960003946 selegiline Drugs 0.000 title abstract 4
- 239000002775 capsule Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 16
- IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 claims description 32
- 229960003678 selegiline hydrochloride Drugs 0.000 claims description 32
- 239000008213 purified water Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
- 238000005563 spheronization Methods 0.000 claims description 7
- 239000000080 wetting agent Substances 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 229950005770 hyprolose Drugs 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims 1
- 238000001125 extrusion Methods 0.000 abstract 1
- 238000005429 filling process Methods 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 238000005096 rolling process Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 3
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 229940016341 selegiline hydrochloride 5 mg Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
参数 | 常规技术制备 | 本发明制备 |
含量均匀度(A+1.80S值) | 14.1 | 10.6 |
装量差异范围 | ±5.0%其中有一粒超出该范围 | 所测重量都在±3.0%内 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310065036.3A CN104013595B (zh) | 2013-03-01 | 2013-03-01 | 一种盐酸司来吉兰制剂及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310065036.3A CN104013595B (zh) | 2013-03-01 | 2013-03-01 | 一种盐酸司来吉兰制剂及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104013595A true CN104013595A (zh) | 2014-09-03 |
CN104013595B CN104013595B (zh) | 2016-08-24 |
Family
ID=51430782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310065036.3A Active CN104013595B (zh) | 2013-03-01 | 2013-03-01 | 一种盐酸司来吉兰制剂及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104013595B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104622826A (zh) * | 2015-03-02 | 2015-05-20 | 孙巧玲 | 一种枸橼酸莫沙必利片剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2280604A (en) * | 1993-07-02 | 1995-02-08 | Resource Medical Limited | Tablet formulation of betahistine and selegiline |
US5817336A (en) * | 1993-04-02 | 1998-10-06 | Orion-Yhtyma Oy | Composition containing selegiline |
-
2013
- 2013-03-01 CN CN201310065036.3A patent/CN104013595B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817336A (en) * | 1993-04-02 | 1998-10-06 | Orion-Yhtyma Oy | Composition containing selegiline |
GB2280604A (en) * | 1993-07-02 | 1995-02-08 | Resource Medical Limited | Tablet formulation of betahistine and selegiline |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104622826A (zh) * | 2015-03-02 | 2015-05-20 | 孙巧玲 | 一种枸橼酸莫沙必利片剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104013595B (zh) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104055743B (zh) | 一种含利伐沙班口服制剂的制备方法 | |
CN102688252A (zh) | 一种阿卡波糖口服固体制剂组合物及其制备方法 | |
CN104510717B (zh) | 奥氮平口崩片及其制备方法 | |
CN103520169A (zh) | 米氮平片及其制备方法 | |
CN104013595A (zh) | 一种盐酸司来吉兰制剂及其制备工艺 | |
CN104622854A (zh) | 含有盐酸氨溴索和硫酸沙丁胺醇的片剂 | |
Huang et al. | Metoprolol tartrate sustained-release binary matrix microspheres for oral administration produced by novel ultra-fine particle processing system | |
CN102349915A (zh) | 一种氨酚咖敏维c制剂及其制备方法 | |
CN104983711A (zh) | 一种盐酸维拉佐酮胶囊组合物 | |
CN108186580A (zh) | 石杉碱甲缓释微球及其制备方法和应用 | |
CN104069082A (zh) | 一种门冬氨酸钾片及其制备方法 | |
CN105496979A (zh) | 一种雷沙吉兰片剂 | |
CN102429883A (zh) | 盐酸氟西汀口腔崩解药物组合物 | |
CN103989643B (zh) | 含有雷美替胺和共聚维酮的片剂 | |
CN113616613A (zh) | 一种治疗糖尿病用药二甲双胍格列吡嗪复方片剂及其制备方法 | |
CN104510723A (zh) | 一种盐酸拉贝洛尔缓释胶囊及其制备方法 | |
CN104606170A (zh) | 一种盐酸氨溴索胶囊及其制备方法 | |
CN105641706A (zh) | 一种米拉贝隆药物组合物及其制备方法 | |
CN104434854B (zh) | 一种米诺膦酸片处方及其制备工艺 | |
CN102784116A (zh) | 一种高溶出度非诺贝特分散片及其制备方法 | |
CN103908437B (zh) | 一种苯扎贝特缓释制剂及其制备方法 | |
CN103315983A (zh) | 一种雷沙吉兰制剂及其制备方法 | |
CN103908435A (zh) | 一种氟他胺缓释制剂及其制备方法 | |
CN105380917B (zh) | 一种盐酸普拉克索缓释片及其制备方法 | |
CN103919739B (zh) | 一种瑞格列奈普通片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hydrochloric acid selegiline preparation and preparation process thereof Effective date of registration: 20190328 Granted publication date: 20160824 Pledgee: Hefei high tech Company limited by guarantee Pledgor: Anhui Biochem Bio-Pharmaceutical Co., Ltd. Registration number: 2019340000162 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200722 Granted publication date: 20160824 Pledgee: Hefei high tech Company limited by guarantee Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: 2019340000162 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation of selegiline hydrochloride and its preparation technology Effective date of registration: 20201222 Granted publication date: 20160824 Pledgee: China Construction Bank Taihe sub branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2020340000064 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211227 Granted publication date: 20160824 Pledgee: China Construction Bank Taihe sub branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2020340000064 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Selegilan hydrochloride preparation and its preparation process Effective date of registration: 20211230 Granted publication date: 20160824 Pledgee: China Construction Bank Taihe sub branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2021340000043 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |